How INO-3106 works
HPV infection can be the cause of some cases of aerodigestive cancer, which involves tumors forming in the mouth, throat, voice box, or sinuses. INO-3106 targets tumors specifically caused by HPV type 6 (HPV-6).
INO-3106 is a DNA-based cancer vaccine, produced using Inovio’s proprietary SynCon technology. A cancer vaccine acts to help “educate” the immune system on particular antigens (or foreign substances associated with a disease that triggers an immune response) so that it can track down and remove the tumor cells. INO-3106 is a plasmid, a piece of circular DNA that can promote the expression of an inserted gene, containing certain genes of HPV-6 called E6 and E7.
Following the administration of INO-3106, the immune system will recognize the E6 and E7 proteins as foreign and mount a response against them. This triggers the production of cytotoxic T lymphocytes (CTLs), or killer T-cells, a type of immune cell that will identify and destroy cells expressing the antigen. This should result in a targeted decrease of the HPV-6-infected tumor cells.
INO-3106 in clinical trials
In September 2014, Inovio initiated a Phase 1 clinical trial (NCT02241369) to assess the safety, tolerability, and immunogenicity (ability to trigger an immune response) of INO-3106 alone or in combination with INO-9012.
INO-9012 is a DNA plasmid containing the immune activator IL-12. The activity of IL-12 may boost the immune response produced by INO-3106, as one of its roles is to increase the production of CTLs.
The trial is using a dose escalation method in an estimated six patients to determine the maximum tolerated dose of INO-3106. Its primary goal is to monitor for adverse events for up to two years following the vaccination. It will also confirm the level of immune response against HPV-6 tumor cells produced by INO-3106. It is currently recruiting participants with HPV-6-associated aerodigestive precancers and cancers at the University of Pennsylvania.
INO-3106 is delivered into cells using Inovio’s Cellectra device, which involves an injection into the muscle and electroporation (a small electrical pulse).
Immuno-Oncology News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.